Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials
Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies Calvert Labs shall perform TRP-8803 and TRP-8802 are psilocybin-based products being evaluated under Tryp’s PFN program Tryp intends to use TRP-8802 in the Phase 2a clinical trials, while TRP-8803 will be used in Phase 2b clinical trials and beyond The San Diego-based pharmaceutical company, Tryp…